Anaptys Phase 2b Misses Primary, Secondary Endpoints in Atopic Dermatitis

 

• ANB032 was well tolerated across all doses with no safety signals observed
• AD trial and all further investment in ANB032 will be discontinued
• Anticipate top-line Phase 2b data in rheumatoid arthritis in February 2025 for rosnilimab, a PD-1+ T cell depleter and agonist
• Funded beyond additional clinical data catalysts including Phase 2 data in ulcerative colitis for rosnilimab and Phase 1b data for ANB033 and ANB101
• Year-end 2024 cash of approximately $415 million and extending cash runway guidance through year-end 2027, excluding potential GSK milestones and royalties

https://www.globenewswire.com/news-release/2024/12/11/2995401/0/en/Anaptys-Announces-Phase-2b-Trial-of-ANB032-a-BTLA-Agonist-Did-Not-Meet-Primary-or-Secondary-Endpoints-in-Atopic-Dermatitis.html